# Links between gut microbiome composition and fatty liver disease in a large population sample

1

2

-	an Se Population Sumple
3	
4 5	Matti O. Ruuskanen <sup>1,2*</sup> , Fredrik Åberg <sup>3,4</sup> , Ville Männistö <sup>5,6</sup> , Aki S. Havulinna <sup>2,7</sup> , Guillaume Méric <sup>8,9</sup> , Yang Liu <sup>8,10</sup> , Rohit Loomba <sup>11,12</sup> , Yoshiki Vázquez-Baeza <sup>13,14</sup> , Anupriya Tripathi <sup>15,16,17</sup> , Liisa M.
6	Valsta <sup>2</sup> , Michael Inouye <sup>8,18</sup> , Pekka Jousilahti <sup>2</sup> , Veikko Salomaa <sup>2</sup> , Mohit Jain <sup>12,19</sup> , Rob Knight <sup>13,14,20,21</sup> ,
7	Leo Lahti <sup>22</sup> , Teemu J. Niiranen <sup>1,2,23</sup>
8	
8 9	<sup>1</sup> Department of Internal Medicine, University of Turku, Turku, Finland
10	<sup>2</sup> Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland
11	<sup>3</sup> Transplantation and Liver Surgery Clinic, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
12	<sup>4</sup> The Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden
13	<sup>5</sup> Department of Medicine, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland
14	<sup>6</sup> Department of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The
15	Netherlands
16 17	<sup>7</sup> Institute for Molecular Medicine Finland, FIMM - HiLIFE, Helsinki, Finland
17	<sup>8</sup> Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia <sup>9</sup> Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia
19	<sup>10</sup> Department of Clinical Pathology, The University of Melbourne, Melbourne, Victoria, Australia
20	<sup>11</sup> Department of Medicine, NAFLD Research Center, La Jolla, CA, USA
$\overline{21}$	<sup>12</sup> Department of Medicine, University of California, San Diego, La Jolla, CA, USA
22	<sup>13</sup> Jacobs School of Engineering, University of California, San Diego, La Jolla, CA, USA
23	<sup>14</sup> Center for Microbiome Innovation, University of California San Diego, La Jolla, California, USA
24	<sup>15</sup> Collaborative Mass Spectrometry Innovation Center, Skaggs School of Pharmacy and Pharmaceutical Sciences,
25	University of California, San Diego, La Jolla, California, USA
26	<sup>16</sup> Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, USA
27	<sup>17</sup> Division of Biological Sciences, University of California, San Diego, La Jolla, California, USA
28	<sup>18</sup> Department of Public Health and Primary Care, Cambridge University, Cambridge, United Kingdom
29 30	<sup>19</sup> Department of Pharmacology, University of California San Diego, La Jolla, California, USA <sup>20</sup> Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA
31	<sup>21</sup> Department of Computer Science & Engineering, University of California San Diego, La Joha, California, USA
32	<sup>22</sup> Department of Future Technologies, University of Turku, Turku, Finland
33	<sup>23</sup> Division of Medicine, Turku University Hospital, Turku, Finland
34	
35	*Correspondence: Matti Ruuskanen, matti.ruuskanen@utu.fi
36	Correspondence. Matti Radiskanen, <u>matti.radiskanen e ata.ri</u>
30 37	Bunning heads Gut migraphicms composition and fatty liver
51	Running head: Gut microbiome composition and fatty liver
38	

Gut microbiome composition and fatty liver 1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 39 Abstract

40 **Background.** Fatty liver disease is the most common liver disease in the world. It is characterized by a 41 build-up of excess fat in the liver that can lead to cirrhosis and liver failure. The link between fatty liver 42 disease and gut microbiome has been known for at least 80 years. However, this association remains 43 mostly unstudied in the general population because of underdiagnosis and small sample sizes. To 44 address this knowledge gap, we studied the link between the Fatty Liver Index (FLI), a well-established proxy for fatty liver disease, and gut microbiome composition in a representative, ethnically 45 46 homogeneous population sample in Finland. We based our models on biometric covariates and phylogenetically transformed gut microbiome compositions from shallow metagenome sequencing. 47 48 **Results.** Our classification models were able to discriminate between individuals with a high FLI ( $\geq$ 49 60, indicates likely liver steatosis) and low FLI (< 60) in our validation set, consisting of 30% of the 50 data not used in model training, with an average AUC of 0.75. In addition to age and sex, our models 51 included differences in 11 microbial groups from class *Clostridia*, mostly belonging to orders 52 Lachnospirales and Oscillospirales. Pathway analysis of representative genomes of the FLI-associated 53 taxa in (NCBI) *Clostridium* subclusters IV and XIVa indicated the presence of *e.g.*, ethanol 54 fermentation pathways. Conclusions. Through modeling the fatty liver index, our results provide with high resolution 55 associations between gut microbiota composition and fatty liver in a large representative population 56 57 cohort. Our results lend further support to the role of endogenous ethanol producers in the development

58 of fatty liver.

59

#### 60 Keywords: Metagenomics, human gut, fatty liver, fatty liver index, population sample

### 61 Background

62 Fatty liver disease affects roughly a quarter of the world's population (Younossi et al., 2016). It is 63 characterized by accumulation of fat in the liver cells and is intimately linked with pathophysiology of 64 metabolic syndrome (Marchesini et al., 2003; Chalasani et al., 2012; Yki-Järvinen, 2014). Fatty liver disease can be broadly divided into two variants: non-alcoholic fatty liver disease (NAFLD), attributed 65 to high caloric intake, and alcohol associated fatty liver disease, attributed to high alcohol consumption. 66 Even though the rate of progressions and underlying causes of both diseases might be different, they 67 68 can be broadly sub-divided into those who have fat accumulation in the liver with no or minimal 69 inflammation or those who have additional features of cellular injury and active inflammation with or 70 without fibrosis typically seen in peri-sinusoidal area. (Toshikuni et al., 2014). Patients with 71 steatohepatitis may progress to cirrhosis and hepatocellular carcinoma and have increased risk of liver-72 related morbidity and mortality, globally amounting to hundreds of thousands of deaths (Rinella and 73 Charlton, 2016).

74

The human gut harbors up to  $10^{12}$  microbes per gram of content (Gilbert et al., 2018) and is intimately 75 76 connected with the liver. Thus, it is no surprise that gut microbiome composition appears to have a 77 strong connection with liver disease (Caussy et al., 2019). Numerous studies over the past 80 years have reported associations between gut microbial composition and liver disease (Compare et al., 2012). 78 79 For example, gut permeability and overgrowth of bacteria in the small intestine (Miele et al., 2009), 80 changes in *Gammaproteobacteria* and *Erysipelotrichi* abundance during choline deficiency (Spencer et 81 al., 2011), elevated abundance of ethanol-producing bacteria (Zhu et al., 2013; Yuan et al., 2019), 82 metagenomic signatures of specific bacterial species (Loomba et al., 2017; Jiao et al., 2019) have all 83 been linked to NAFLD in small case-control patient samples. However, the microbial signatures often 84 overlap between NAFLD and metabolic diseases, while those of more serious liver disease such as Gut microbiome composition and fatty liver 3

steatohepatitis and cirrhosis are more clear (Aron-Wisnewsky et al., 2020). For example, oral taxa appear to invade the gut in liver cirrhosis (Qin et al., 2014), and this phenotype can accurately be detected by analyzing the fecal microbiome composition (AUC = 0.87 in a validation cohort; Caussy et al., 2019). Furthermore, we recently demonstrated good prediction accuracy for incident liver disease diagnoses (AUC = 0.83 for non-alcoholic liver disease, AUC = 0.96 for alcoholic liver disease, during ~15 years), showing that the signatures of serious future liver disease are easy to detect (Liu et al.,

91 2020).

92

93 The mechanisms underlying the contribution of gut microbiome content with fatty liver disease are 94 thought to be primarily linked to gut bacterial metabolism. Bacterial metabolites can indeed be 95 translocated from the gut through the intestinal barrier into the portal vein and transported to the liver, 96 where they interact with liver cells, and can lead to inflammation and steatosis (Safari and Gérard, 97 2019). Short-chain fatty acid production, conversion of choline into methylamines, modification of bile 98 acids (BA) into secondary BA, and ethanol production, all of which are mediated by gut bacteria, are 99 also known to be aggravating factors for NAFLD (Safari and Gérard, 2019). Recent studies have also 100 suggested that endogenous ethanol production by gut bacteria could lead to an increase in gut 101 membrane permeability (Yuan et al., 2019). This can facilitate the translocation of bacterial metabolites 102 and cell components such as lipopolysaccharides from the gut to the liver, leading to further 103 inflammation and possible development of NAFLD (Carpino et al., 2019).

104

Liver biopsy assessment is the current gold standard for diagnosis of fatty liver disease and its severity (Li et al., 2018), but it is also impractical and unethical in a population-based setting. Ultrasound and MRI based assessment can help detect presence of fatty liver, however, this data is not available in our cohort. Regardless, recent studies have shown that indices based on anthropometric measurements and

109 standard blood tests can be a reliable tool for non-invasive diagnosis of fatty liver particularly in 110 population-based epidemiologic studies (Koehler et al., 2013; Vanni and Bugianesi, 2015). 111 Here, we designed and conducted computational analyses to examine the links between fatty liver and 112 gut microbiome composition in a representative population sample of 7211 extensively phenotyped 113 Finnish individuals (Salosensaari et al., 2020). Because fatty liver disease is generally underdiagnosed 114 in the general population (Alexander et al., 2018), we used population-wide measurements of BMI, 115 waist circumference, blood triglycerides and gamma-glutamyl-transferase (GGT) to calculate a 116 previously validated Fatty Liver Index (FLI) for each participant as a proxy for fatty liver (Bedogni et 117 al., 2006). In parallel, we used shallow shotgun sequencing to analyze gut microbiome composition 118 (Hillmann et al., 2018), which also enabled the use of phylogenetic and pathway prediction methods. In 119 this work, we describe high-resolution associations between fatty liver and individual gut microbial

120 taxa and clades, which are generalizable at the population level.

121

# 122 **Results**

#### 123 Bacterial community structure is correlated with Fatty Liver Index in a population

124 sample

To investigate the link between fatty liver disease (using FLI as a proxy; Figure 1A, 1B) and gut 125 microbial composition, we used linear regression (adjusted  $R^2 = 0.29$ ) on the three first principal 126 127 component (PC) axes of the fecal bacterial beta-diversity (between individuals), sex, age, and alcohol 128 to model FLI. log<sub>10</sub>(FLI) significantly correlated with all three bacterial PC axes, sex, age, and alcohol 129 use (all  $P < 1 \times 10^{-6}$ ). Correlations between FLI and archaeal PC axes were not significant (P > 0.05). 130 The effect size estimate on  $\log_{10}$ (FLI) was a magnitude larger for PC1 (0.11 ± 0.008) than for PC2 131  $(0.04 \pm 0.008)$  and PC3 (-0.06  $\pm 0.008$ ). The relationships between FLI and the bacterial PC 132 components representing their beta-diversity are visualized for each of the three components in **Figure** Gut microbiome composition and fatty liver 5

1C. In our analyses, we classified our reads against the Genome Taxonomy Database (GTDB; Parks et al., 2018), and thus the taxonomy discussed in this study follows the standardized GTDB taxonomy, unless otherwise noted.

136

137 Bacterial clades with the highest positive loadings on PC1 (and therefore associated with higher FLI values) included members of the Lachnospirales and Oscillospirales taxonomic orders, of the Bacilli 138 139 class, and of the *Ruminococcaceae*, *Bacteroidaceae* and *Lachnospiraceae* families (Figure S2). These 140 observations led us to further analyses within a machine learning framework to estimate the relative 141 contributions of individual bacterial taxa to the differences in FLI between study participants. 142 Bacterial lineages within the NCBI Clostridium subclusters IV and XIVa associate with 143 FLI 144 145 In our machine learning framework, we used the known covariates in addition to individual archaeal 146 and bacterial "balances" as the predicting features. Briefly, each balance represents a single internal 147 node in a phylogenetic tree, and its value is a log-ratio of the abundances of the two clades descending 148 this node (for details see methods, and Silverman et al., 2017). Continuous FLI and differences 149 between FLI groups (FLI < 60, N = 4359 and FLI  $\geq 60$ , N = 1910; see Figures 1A, 1B) were modeled 150 with gradient boosting regression or classification using Leave-One-Group-Out Cross-Validation 151 (LOGOCV) between participants from different regions. 152 153 After feature selection and Bayesian hyperparameter optimization, the correlation between the 154 predictions of the final regression models (age, sex, self-reported alcohol use, and 18 bacterial balances 155 as features; each trained on the data from 5/6 regions) and true values in unseen data from the omitted region averaged  $R^2 = 0.30 (0.26 - 0.33)$ . After feature selection and optimization, the main 156

157	classification models (age, sex, and 11 bacterial balances as features; each trained on the data from 5/6
158	regions) averaged AUC = $0.75$ ( <b>Table S1</b> ) and AUPRC = $0.56$ (baseline at 0.30; <b>Table S2</b> ) on (unseen)
159	test data from the omitted region. Models trained using only the covariates averaged AUC = $0.71$
160	(AUPRC = $0.47$ ) and using only the 11 bacterial balances they averaged AUC = $0.66$ (AUPRC = $0.47$ )
161	on test data. Alternative models were constructed by excluding participants with FLI between 30 and
162	60 (N = 1583) and discerning between groups of FLI < 30 (N = 2776) and FLI $\ge$ 60 (N = 1910). These
163	models averaged AUC = $0.80$ (AUPRC = $0.75$ , baseline at $0.41$ ) on their respective test data. They
164	averaged AUC = $0.76$ (AUPRC = $0.68$ ) when using only the covariates, and AUC = $0.70$ (AUPRC =
165	0.63) when using only the 20 bacterial balances.
166	

Because training data from all 6 regions was used to prevent overfitting in the selection of core features 167 168 for all of the models, and similarly in searching for common hyperparameters, participants from the 169 validation region of each model (in the training partition) partly influenced these parameters. Thus, we also constructed classification models discerning between the FLI < 60 and FLI  $\ge$  60 groups, where 170 171 data of the validation region was completely excluded in the feature selection and hyperparameter 172 optimization of each LOGOCV model. These models, using their individual feature sets and 173 hyperparameters, averaged AUC = 0.75 and AUPRC = 0.57 (baseline at 0.30) on test data from their 174 respective validation regions (Table S3). Using only covariates, they averaged AUC = 0.71 (AUPRC = 175 0.47), and AUC = 0.67 (AUPRC = 0.48) with only the bacterial balances. 176

To facilitate interpretability of the results, we primarily continued examining the main classification models using a common set of core features. In these models, the median effect sizes of the features on the model predictions at their minimum and maximum values were highest for age, followed by sex, and the 11 balances in the phylogenetic tree (**Figures S2, S3**). All 11 associated balances were in

7

181 phylum *Firmicutes*, class *Clostridia*, and largely in the NCBI *Clostridium* subclusters IV and XIVa

182 (Figure 2). The specific taxa represented standardized GTDB genera (NCBI in brackets)

183 Negativibacillus (Clostridium), Clostridium M (Lachnoclostridium / Clostridium), CAG-81

184 (Clostridium), Dorea (Merdimonas / Mordavella / Dorea / Clostridium / Eubacterium), Faecalicatena

185 (Blautia / Ruminococcus / Clostridium), Blautia (Blautia), Sellimonas (Sellimonas / Drancourtella),

186 *Clostridium Q* (*Lachnoclostridium* [*Clostridium*]) and *Tyzzerella* (*Tyzzerella / Coprococcus*). Notably,

187 all but one of the features in the main classification models (n226) were identified in the feature

188 selection for the alternative models (constructed otherwise identically, but FLI < 30 was compared

against  $FLI \ge 60$  in different data partitions), together with 10 additional balances (Figure S4). Only

190 one of the balances in the alternative models was outside phylum *Firmicutes* (n1712 in *Bacteroidota*),

and in addition, 4 balances were outside class *Clostridia* (n481 in *Negativicutes*; n826, n1009 and n918

192 in Bacilli).

193

194 In addition to blood test results, FLI is based on anthropometric markers linked to metabolic syndrome, 195 waist circumference and BMI. This prompted us to attempt to dissect the index and identify which of 196 the covariates and associated microbial balances from the phylogenetic tree can be linked to blood 197 GGT and triglycerides measurements (see Figure 1B), and therefore would be more specific to hepatic 198 steatosis and liver damage. To do so, we performed feature selection (similarly to continuous FLI) for GGT and triglycerides measurements in subsets of participants grouped by age, sex, and BMI. The 199 200 feature selection identified two balances within the NCBI Clostridia XIVa subcluster (identified as 201 n336 and n330) which were important for both GGT and triglyceride level prediction, and thus likely 202 specific to liver function (Figure 2). Bacterial taxa were positively linked to liver function in these 203 balances, and included (NCBI species) Clostridium clostridioforme, C. bolteae, C. citroniae, C. 204 saccharolyticum and C. symbiosum.

8

205

# Ethanol and acetate production pathways are identified in representative bacterial genomes from taxa linked to liver function

The values of predictive balances in the phylogenetic tree cannot be summarized for individual taxa, which means that only a qualitative investigation of the associations between their metabolism and fatty liver was possible in this study. We identified genetic pathways predicted to encode for SCFA (acetate, propanoate, butanoate) and ethanol production, BA metabolism, and choline degradation to trimethylamine in representative genomes from the taxa we identified to be linked to liver function (**Figure S3**). These specific processes were chosen because they have been previously identified to have a mechanistic link to NAFLD (see *e.g.*, Safari and Gérard, 2019).

215

216 Acetate and ethanol production pathways appeared to be more abundant in the representative genomes 217 of the taxa which had a positive association with FLI. In the liver function specific clades, n336 and 218 n330, MetaCyc pathways for pyruvate fermentation to ethanol III (PWY-6587) and L-glutamate 219 degradation V (via hydroxyglutarate; P162-PWY; produces acetate and butanoate) were present only in 220 genomes positively associated with FLI. In balance n336, also heterolactic fermentation (P122-PWY; 221 produces ethanol and lactate) was more often encoded in the FLI-associated clade (3/5) than the 222 opposing clade (1/2). In representative genomes from the non-liver-specific balance n355, potential 223 ethanol producers (PWY-6587) were seen in the positively associated clade, but for most balances such 224 trends were not clear in the qualitative analysis. Furthermore, we did not detect any of these pathways 225 in the representative genomes of two individual taxa positively associated with FLI, Negativibacillus 226 sp000435195 and Phocea massiliensis (Figure S3).

9

227

# 228 Discussion

229 The pathophysiology of fatty liver disease in general, and NAFLD in particular, is complex and its 230 clinical diagnosis can be difficult (Haas et al., 2016). In this study, we leveraged multi-omics data 231 from a large population study (FINRISK02) to identify broad links between the overall gut 232 microbiome composition and fatty liver disease, using FLI as a recognized proxy (Figure 1C), and 233 identified specific microbial taxa and lineages predictive of a higher FLI (Figure 2). Considering that 234 the predictive ability of FLI for clinically diagnosed NAFLD ranges between AUC = 0.81 - 0.93, in 235 populations of Caucasian ethnicity such as ours (Vanni and Bugianesi, 2015), our models were able to 236 reasonably predict the FLI group with AUC = 0.75 (AUPRC = 0.56, baseline at 0.30), while 237 extrapolating to a validation region not used in training of the model. 238 239 Our additional analyses support these results. Excluding participants with intermediate FLI (between 240 30-60 increased the accuracy slightly (to AUC = 0.8 and AUPRC = 0.75, baseline at 0.41). 241 However, discerning between participants with probable fatty liver disease (FLI  $\geq$  60) from others 242 presents a clinically more relevant target for detecting changes in microbiome composition associated 243 with development of the disease. In another set of models, we negated the influence of validation 244 region data in the individual models also for feature selection and hyperparameter optimization during training. This led to individualized sets of features and parameters in the models, but the average 245 246 performance of the models was almost identical on validation region samples in the test data (AUC = 247 0.75 and AUPRC 0.57, baseline at 0.30). The aim of our study was to find patterns in microbiome 248 composition which would be generalizable across the 6 sampled geographic regions in Finland and 249 easy to interpret. Thus, we consider the use of all training data to define the common core feature set 250 justified. This goal also guided our overall modeling architecture and likely led to a lower 251 performance than if we instead performed interpolation within a smaller scale (*e.g.*, He et al., 2018). Gut microbiome composition and fatty liver 10

252

When interpreting results, several different levels of associations can be considered according to types of fatty liver disease and the gut microbiome composition. Because FLI has been mostly validated with simple steatosis and NAFLD (Bedogni et al., 2006; Vanni and Bugianesi, 2015), we can conservatively contextualize our findings with previous associative work that used these diagnoses or clinical manifestations, only.

258

# FLI modeling reveals consistent associations between gram-positive *Clostridia* and fatty liver disease

261 We found significant linear correlations between the first three bacterial PC-axes of our samples (a 262 measure of beta diversity) and FLI (see results and Figure 1C). Previous studies have shown 263 differences in beta diversity in relation to NAFLD (Kim et al., 2019). However, FLI used in our study 264 as a proxy for liver disease also includes features such as BMI and waist circumference, which 265 associate with metabolic syndrome and type 2 diabetes (Aron-Wisnewsky et al., 2020). Links between these diseases and gut microbiome composition are well documented in previous studies 266 267 (Castaner et al., 2018). It is thus not surprising that bacterial beta diversity and FLI were correlated, 268 but unfortunately this simple correlation does not enable untangling the relative contributions of fatty 269 liver disease and other metabolic diseases to the differences in bacterial beta diversity.

270

Several studies have reported highly specific changes in microbial abundances in relation to NAFLD
(Wigg et al., 2001; Mouzaki et al., 2013; Zhu et al., 2013; Shen et al., 2017). In summary, while also
conflicting results have been reported, generally increases in *Lactobacillus* and *Escherichia* genera,
and a decrease in *Coprococcus* genus have been most often associated with a NAFLD diagnosis
(Sharpton et al., 2019). Furthermore, increased abundance of several gram-positive bacteria belonging

to the *Clostridium* genus have often been positively linked with NAFLD (Jiang et al., 2015; Loomba
et al., 2017). Differences in unconstrained between-samples (beta) diversity have been also
documented for persistent NAFLD (Kim et al., 2019) and along the NAFLD-cirrhosis spectrum
(Caussy et al., 2019).

280

In our study, abundances of bacteria from the Coprococcus genus were not specifically associated 281 282 with FLI, although the genus was nested inside our predictive balances. Strikingly, we did not 283 identify any bacterial associations with FLI outside of the Firmicutes phylum. A possible reason for 284 this might be the higher relative abundance of phylum *Firmicutes* at high latitudes, where Finland is 285 (Suzuki and Worobey, 2014). Among the associations we identified, *Faecalicatena gnavus* (NCBI: 286 *Ruminococcus gnavus*) was positively linked with FLI as part of 3 predictive balances, and associated 287 in previous studies with liver cirrhosis (Qin et al., 2014). Interestingly, none of the oral *Firmicutes*, 288 such as Veillonella, suggested to invade the gut, were identified in our own analyses. This might be 289 caused by using FLI as a proxy, which is likely not closely associated with advanced liver disease, 290 such as cirrhosis, and thus would target an earlier phase of liver disease progression.

291

292 Two individual taxa, Negativibacillus sp000435195 and Phocea massiliensis, were highly predictive 293 of FLI group (Figures 2, S2), but not of its liver function-specific components. The associations of 294 these taxa with fatty liver disease have not been documented previously. However, a decreasing 295 abundance of both bacteria, Negativibacillus sp000435195 (NCBI: Clostridium sp. CAG:169) and 296 Phocea massiliensis (NCBI: Phocea massiliensis), were seen when the intake of meat and refined 297 cereal was reduced isocalorically in favor of fruit, vegetables, wholegrain cereal, legumes, fish and 298 nuts in overweight and obese subjects in Italy (Meslier et al., 2020). While comparisons between 299 these studies are difficult due to annotation, bacteria such as Faecalicatena gnavus (NCBI:

*Ruminococcus gnavus*) and *Clostridium Q saccharolyticum* (NCBI: *Clostridium saccharolyticum*)
were also found to respond negatively to the Mediterranean diet. Together with their positive
association with FLI in our study, these observations would warrant further study on these species as
plausible biomarkers for healthy diet choices.

304

305 Most taxa in our study with a positive association with FLI belonged to the (broadly defined) 306 *Clostridium* NCBI genus, which supports several previous observations (Jiang et al., 2015; Loomba et 307 al., 2017). However, taxonomic standardization according to GTDB has identified the *Clostridium* 308 genus as the most phylogenetically inconsistent of all bacterial genera in the NCBI taxonomy, and 309 divides it into a total of 121 monophyletic genera in 29 distinct families (Parks et al., 2018). These 310 reassignments, although more accurate and sensible, complicate comparisons to previous research 311 studies. However, our results strongly suggest that this finer taxonomic resolution might robustly 312 reveal novel discoveries. Thus, while (shallow) shotgun metagenomic sequencing is often more costly 313 than amplicon sequencing, this might be justified by the increased resolution which is required to 314 accurately identify specific taxon-based associations (e.g., Hillmann et al., 2018, 2020).

315

# **Bacterial taxa associated with a high FLI have a genetic potential to exacerbate the**

## 317 development of fatty liver disease

We identified several plausible new associations between individual taxa and clades of bacteria and fatty liver. All taxa were from class *Clostridia*, which are obligate anaerobes. We observed that reference genomes from the bacterial taxa positively associated with FLI in the liver-specific balances harbored several genetic pathways necessary for ethanol production. Specifically, genes predicted to enable the fermentation of pyruvate to ethanol (MetaCyc PWY-6587) appeared to be common. Endogenous production of ethanol has been known to both induce hepatic steatosis and increase

intestinal permeability (de Faria Ghetti et al., 2018) and several of the taxa identified in our study
have also been experimentally shown to produce ethanol, such as *C. M asparagiforme, C. M bolteae*, *C. M clostridioforme / C. M clostridioforme A* (Mohan et al., 2006), and *C. Q Saccharolyticum*(Murray et al., 1982). The relative abundances of these putatively ethanol-producing taxa were
predictive of FLI groups in previously unseen data. However, the self-reported alcohol consumption
from the participants was not among the best predictors for the FLI groups, as it was excluded in the
feature selection step.

331

332 All reference genomes from taxa positively associated with FLI in balance n330 harboured genes 333 predicted to encode for the L-glutamate fermentation V (P162-PWY; Figure S3) pathway, which 334 results in the production of acetate and butanoate. Glutamate fermentation could lead to increased 335 microbial protein fermentation in the gut, which has been previously been linked with obesity, 336 diabetes and NAFLD (Diether and Willing, 2019). Recently, the combined intake of fructose and 337 microbial acetate production in the gut was experimentally observed to contribute to lipogenesis in 338 the liver in a mouse model (Zhao et al., 2020). Interestingly, C. Q saccharolyticum (in our study, a 339 FLI-associated species deriving from balance n330), was experimentally shown to ferment various 340 carbohydrates, including fructose, to acetate, hydrogen, carbon dioxide, and ethanol (Murray et al., 341 1982). Furthermore, while our own pathway analysis did not detect BA modification pathways in the 342 reference genome of C. Q saccharolyticum, a strain of this species has been highlighted as a probable 343 contributor to NAFLD development through the synthesis of secondary BA (Jiao et al., 2019). The 344 links between dietary intake and gene regulation, combined with microbial fermentation in the gut 345 warrant further mechanistic experiments to elucidate their links with fatty liver, and likely other 346 metabolic diseases.

347

348 Intriguingly, NAFLD-associated ethanol producing bacteria in previous cohort studies have all been 349 gram-negatives, such as (NCBI-defined) Klebsiella pneumoniae (Yuan et al., 2019) and Escherichia 350 *coli* (Zhu et al., 2013). In our population sample, instead of gram-negatives, bacteria from the C. M 351 bolteae, C. M clostridioforme / C. M clostridioforme A and C. M citroniae species (linked in our 352 study with FLI as deriving from balance n336) have been described as opportunistic pathogens 353 (Dehoux et al., 2016), and are hypothesized to exacerbate fatty liver development similarly through 354 endogenous ethanol production. This result suggests that geographical (He et al., 2018) and ethnic 355 (Deschasaux et al., 2018) variability might also strongly affect gut microbiome composition and its 356 associations with disease. In addition to putative endogenous ethanol producers, we identified other 357 FLI-associated taxa deriving from balance n330, for which reference genomes harbored a genetic 358 pathway predicted to encode for the ability to ferment L-lysine to acetate and butyrate. While the 359 production of these SCFAs is often considered beneficial for gut health, other metabolism of 360 proteolytic bacteria might negatively contribute to fatty liver disease (Canfora et al., 2019).

361

362 Through modeling a previously validated risk index for fatty liver, we could associate specific 363 members of the gut microbiome with the disease across geographical regions in this representative 364 sample of the general population in Finland. In addition, sex and age of participants were also 365 strongly predictive of the FLI group in our models (Figures 2, S2, Table S1). Their similar positive 366 associations with fatty liver disease are known from previous studies (e.g., Cheng et al., 2013; 367 Lonardo et al., 2019). The associated microbial balances could be used to improve the predictions above the baseline of these covariates on 5/6 regions in Finland. For example, in the model cross-368 369 validated with Lapland the balances were more predictive of FLI group than the covariates by 370 themselves, and their combination increased the AUC further. Yet, when testing the model where 371 Turku/Loimaa region was used for cross-validation, the microbial balances were slightly predictive of

FLI group but failed to improve the AUC over the covariates (**Table S1**). This pattern might stem from the cultural and genetic west-east division in Finland (Näyhä, 1989; Kerminen et al., 2017), with a closer proximity of the Helsinki/Vantaa region to eastern regions than Turku/Loimaa, in both terms. It is thus likely that further incorporation and investigation on the use of spatial information in microbiome modeling would elucidate these geographical patterns in taxa-disease associations.

377

## 378 Conclusions

379 Modeling an established risk index for fatty liver enabled the detection of associations between the 380 disease and gut microbiome composition, even to the level of individual taxa. These taxa and clades 381 were all from the obligately anaerobic gram-positive class *Clostridia*, from several redefined GTDB 382 genera previously included in the polyphyletic NCBI genus *Clostridium*. Many of the representative 383 genomes of taxa positively associated with fatty liver had genomic potential for endogenous ethanol 384 production. This suggests a possible mechanistic link to the pathophysiology of liver disease through 385 increased gut permeability and induction of hepatic steatosis. Further mechanistic links with 386 microbial production of SCFAs, especially acetate, and fatty liver development are also likely. Our 387 models were able to predict the FLI group of participants across geographical regions in Finland, 388 showing that the associations are robust and mostly generalizable in the sampled population. 389

# 390 Methods

#### 391 Survey details and sample collection

Cardiovascular disease risk factors have been monitored in Finland since 1972 by conducting a
representative population survey every five years (Borodulin et al., 2018). In the FINRISK 2002
survey, a stratified random population sample was conducted on six geographical regions in Finland.

395	These are North Karelia and Northern Savo in eastern Finland, Turku and Loimaa regions in
396	southwestern Finland, the cities of Helsinki and Vantaa in the capital region, the provinces of Northern
397	Ostrobothnia and Kainuu in northwestern Finland, and the province of Lapland in northern Finland.
398	

399 Briefly, at baseline examination the participants filled out a questionnaire form, and trained nurses 400 carried out a physical examination and blood sampling in local health centers or other survey sites. 401 Data was collected for physiological measures, biomarkers, and dietary, demographic and lifestyle 402 factors. Stool samples were collected by giving willing participants a stool sampling kit with detailed 403 instructions. These samples were mailed overnight between Monday and Thursday under Finnish 404 winter conditions to the laboratory of the Finnish Institute for Health and Welfare, where they were 405 stored at -20°C. In 2017, the samples were shipped still unthawed to University of California San Diego 406 for microbiome sequencing.

407

Further details of the FINRISK cohorts and sampling have been extensively covered in previous
publications (Borodulin et al., 2015; Salosensaari et al., 2020). The Coordinating Ethics Committee of
the Helsinki University Hospital District approved our study protocol. All participants have given their
written informed consent.

412

#### 413 Stool DNA extraction and shallow shotgun metagenome sequencing

414 A miniaturized version of the Kapa HyperPlus Illumina-compatible library prep kit (Kapa Biosystems)

415 was used for library generation, following the previously published protocol (Sanders et al., 2019).

416 DNA extracts were normalized to 5 ng total input per sample in an Echo 550 acoustic liquid handling

417 robot (Labcyte Inc). A Mosquito HV liquid-handling robot (TTP Labtech Inc was used for 1/10 scale

418 enzymatic fragmentation, end-repair, and adapter-ligation reactions). Sequencing adapters were based

on the iTru protocol (Glenn et al., 2019), in which short universal adapter stubs are ligated first and
then sample-specific barcoded sequences added in a subsequent PCR step. Amplified and barcoded
libraries were then quantified by the PicoGreen assay and pooled in approximately equimolar ratios
before being sequenced on an Illumina HiSeq 4000 instrument to an average read count of
approximately 900,000 reads per sample.

424

#### 425 **Taxonomic matching and phylogenetic transforms**

426 To improve the taxonomic assignments of our reads, we used a custom index (Méric et al., 2019) based 427 on the Genome Taxonomy Database (GTDB) release 89 (Parks et al., 2018, 2020) taxonomic 428 redefinitions for read classification with default parameters in Centrifuge 1.0.4 (Kim et al., 2016). After 429 read classification, all following steps were performed with R version 3.5.2 (R Core Team, 2018). To 430 reduce the number of spurious read assignments, and to facilitate more accurate phylogenetic 431 transformations, only reads classified at the species level, matching individual GTDB reference 432 genomes, were retained. Samples with less than 50,000 reads, from pregnant participants or recorded 433 antibiotic use in the past 6 months were removed, resulting in a final number of 6,269 samples. We first 434 filtered taxa not seen with more than 3 counts in at least 1% of samples and those with a coefficient of 435 variation  $\leq$  3 across all samples, following (McMurdie and Holmes, 2013) with a slight adaption from 436 20% of samples to 1% of samples, because of our larger sample size. The complete bacterial and 437 archaeal phylogenetic trees of the GTDB release 89 reference genomes, constructed from an alignment 438 of 120 bacterial or 122 archaeal marker genes (Parks et al., 2018), were then combined with our taxa 439 tables. The resulting trees were thus subset only to species which were observed in at least one sample 440 in our data. The read counts were transformed to phylogenetic node balances in both trees with PhILR (Silverman et al., 2017). The default method for PhILR inputs a pseudocount of 1 for taxa absent in an 441 442 individual sample before the transform.

443

444 In this study, we did not specifically and solely use relative abundances at various taxonomic levels, as 445 is common practice for microbiome studies. Instead, we applied a PhILR transformation to our 446 microbial composition data (Silverman et al., 2017), introducing the concept of microbial "balances". 447 Indeed, evolutionary relationships of all species harbored in each microbiome sample can be 448 represented on a phylogenetic tree, with species typically shown as external nodes that are related to 449 each other by multiple branches connected by internal nodes. In this context, the value of a given 450 microbial "balance" is defined as the log-ratio of the geometric mean abundance between two groups 451 of microbes descending from the same corresponding internal node on a microbial phylogenetic tree. 452 This phylogenetic transform was used because it i) addresses the compositionality of the metagenomic 453 read data (Gloor et al., 2017), ii) permits simultaneous comparison of all clades without merging the 454 taxa by predefined taxonomic levels, and iii) enables evolutionary insights into the microbial 455 community. The links between microbes and their environment, such as the human gut, is mediated by 456 their functions. Different functions are known to be conserved at different taxonomic resolutions, and 457 most often at multiple different resolutions (Louca et al., 2018). Thus, associations between the 458 microbes and the response variable are likely not best explained by predefined taxonomic levels. In the 459 absence of functional data, concurrently analyzing all clades (partitioned by the nodes in the 460 phylogenetic tree) would likely enable the detection of the associations at the appropriate resolution 461 depending on the function and the local tree topography.

462

#### 463 Covariates

Because fatty liver disease is underdiagnosed at the population level (Alexander et al., 2018) and our
sampling did not have extensive coverage of liver fat measurements, we chose to use the Fatty Liver
index (Bedogni et al., 2006) as a proxy for fatty liver. Furthermore, the index performs well in cohorts

467	of Caucasian ethnicity, such as ours, to diagnose the presence of NAFLD (Vanni and Bugianesi, 2015).
468	We calculated FLI after Bedogni et al., (2006): $(e^{0.953*\log_e(triglycerides mg/dL) + 0.139*BMI + 0.718*\log_e(GGT) + 0.139*BMI + 0.139*BMI + 0.718*\log_e(GGT) + 0.139*BMI + 0.139*$
469	$0.053* \text{waist circumference} - 15.745) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GGT}) + 0.053* \text{waist circumference} - 15.745}) / (1 + e^{0.953*\log_e(\text{triglycerides mg/dL}) + 0.139*\text{BMI} + 0.718*\log_e(\text{GT}) + 0.053*\log_e(\text{triglycerides mg/dL}) + 0.053*\log_e(\text{triglycerides mg/dL}) + 0.053*\log_e(\text{GT}) + 0.053*\log_e(\text{triglycerides mg/dL}) + 0.053*\log_e(triglycerides mg/dL$
470	<sup>15.745</sup> ) * 100. We chose the cutoff at $FLI \ge 60$ to identify participants likely to be diagnosed with hepatic
471	steatosis (positive likelihood ratio = $4.3$ and negative likelihood ratio = $0.5$ in Bedogni et al., 2006).
472	Triglycerides, gamma glutamyl transferase (GGT), BMI and waist circumference measurements had
473	near complete coverage for the participants in our data. Self-reported alcohol use was calculated as
474	grams of pure ethanol per week. Cases with missing values were omitted in linear regression models.
475	At least one feature used for FLI calculation was missing for 20 participants (0.3%) and the self-
476	reported alcohol use was missing for 247 participants (3.9%). In the machine learning framework,
477	missing values for FLI and self-reported alcohol use were mean imputed. However, for the feature
478	selection to identify liver function-specific balances, GGT, triglycerides and BMI were not imputed but
479	observations where any of these were missing were simply removed.

480

#### 481 Beta-diversity and linear modeling of FLI

482 Beta-diversity was calculated as Euclidian distance of the PhILR balances through Principal 483 Component Analysis (PCA) on bacterial and archaeal balances separately with 'rda' in vegan 2.5.6 484 (Oksanen et al., 2018). A linear regression model was constructed for FLI with 'lm' in base R (R Core 485 Team, 2018) with  $\log_{10}$ -transformed FLI as the dependent variable and with first three bacterial PCs, sex, age, and self-reported alcohol use as the independent variables. Archaeal PCs were dropped from 486 487 the model because none of them were significantly correlated with FLI (all P > 0.05). Variation of the 488 samples on the top two bacterial PC axes by their effect sizes in the model were plotted together with a 489 unit vector of  $log_{10}$ (FLI) to show their correlation.

490

#### 491 **FLI modeling within a machine learning framework**

492 In the machine learning framework, both regression and categorical models were constructed for FLI. 493 The feature selection, hyperparameter optimization and cross-validation methods were identical for 494 both approaches, unless otherwise stated. The continuous or categorical FLI (groups of FLI < 60 and 495  $FLI \ge 60$ ) were modeled with xgboost 0.90.0.2 (Chen and Guestrin, 2016) by using both bacterial and 496 archaeal balances, sex, age, and self-reported alcohol use as preliminary predictor features. We used 497 FLI 60 as the cutoff for ruling in fatty liver (steatosis) for the classification, after Bedogni et al., (2006). 498 The data was first split to 70% train and 30% test sets while preserving sex and region balance. To take 499 into account geographical differences (e.g., He et al., 2018) and to find robust patterns across all 6 500 sampled regions in Finland between the features and FLI group, we used Leave-One-Group-Out Cross-501 Validation (LOGOCV) inside the 70% train set to construct 6 separate models in each optimization 502 step. Because of high dimensionality of the data (3423 predictor features) feature selection by filtering 503 was first performed inside the training data, based on random forest permutation as recommended by 504 Bommert et al., (2020). Briefly, permutation importance is based on accuracy, or specifically the 505 difference in accuracy between real and permuted (random) values of the specific variable, averaged in 506 all trees across the whole random forest. The permutation importance in models based on the 6 507 LOGOCV subsets of the training data were calculated with mlr 2.16.0 (Bischl et al., 2016) and the 508 simple intersect between the top 50 features in all LOGOCV subsets were retained as the final set of 509 features. Thus, the feature selection was influenced by the training data from all 6 geographical regions, 510 but this only serves to limit the number of chosen features because of the required simple intersect. 511 This approach was used to obtain a set of core predictive features which would have potential for generalizability across the regions. The number of features included in the models by this approach was 512 513 deemed appropriate, since the relative effect size of the last included predictor was very small (< 0.1514 change in classification probability across its range).

5	1	-5
J	T	

516	Bayesian hyperparameter optimization of the xgboost models was then performed with only the
517	selected features. An optimal set of parameters for the xgboost models were searched over all
518	LOGOCV subsets with 'mbo' in mlrMBO 1.1.3 (Bischl et al., 2018), using 30 preliminary rounds with
519	randomized parameters, followed by 100 optimization rounds. Parameters in the xgboost models and
520	their considered ranges were learning rate (eta) [0.001, 0.3], gamma [0.1, 5], maximum depth of a tree
521	[2, 8], minimum child weight [1, 10], fraction of data subsampled per each iteration [0.2, 0.8], fraction
522	of columns subsampled per tree [0.2, 0.9], and maximum number of iterations (nrounds) [50, 5000].
523	The parameters recommended by these searchers were as following for regression: eta=0.00889;
524	gamma=2.08; max_depth=2; min_child_weight=8; subsample=0.783; colsample_bytree=0.672;
525	nrounds=1810, and for classification: eta=0.00107; gamma=0.137; max_depth=5;
526	min_child_weight=9; subsample=0.207; colsample_bytree=0.793; nrounds=4328. We used Root-
527	Mean-Square Error (RMSE) for the regression models and Area Under the ROC Curve (AUC) for the
528	classification models to measure model fit on the left-out data (region) in each LOGOCV subset. The
529	final models were trained on the LOGOCV subset training data, the data from one region thus omitted
530	per model, and using the selected features and optimized hyperparameters. Validation of these models
531	was conducted against participants only from the region omitted from each model, in the 30% test data
532	which was not used in model training or optimization. Sensitivity analysis was conducted by using only
533	the predictive covariates (sex and age) or balances separately, with the same hyperparameters, data
534	partitions and final validation as for the full models.
535	

#### 536 **Partial dependence interpretation of the FLI classification models**

537 Because the classification models have a more clinically relevant modeling target for the difference

538 between FLI < 60 and  $FLI \ge 60$ , the latter used to rule in fatty liver (Bedogni et al., 2006), we further

539 interpreted the partial dependence of their predictions. Partial dependence of the classification model 540 predictions on individual features was calculated with 'partial' in pdp 0.7.0 (Greenwell, 2017). The partial dependence of the features on the model predictions was also plotted, overlaying the results 541 542 from each of the 6 models. For each feature, its relative effect on the model prediction was estimated as 543 medians of the minimum and maximum yhat (output probability of the model for the FLI  $\geq$  60 class), 544 calculated at the minimum and maximum values of the feature separately in each of the 6 models. The 545 relative effects of the balances were then overlaid as a heatmap on a genome cladogram which covers 546 all balances in the model with ggtree 2.1.1 (Yu et al., 2017).

547

#### 548 Construction of alternative classification models to discern between

#### 549 FLI < 30 and FLI $\ge$ 60 groups

550 To assess robustness of the models and how removing the participants with intermediate FLI (between

551 30 and 60) affects model performance, we removed this group (N = 1910) and constructed alternative

classification models to discern between the FLI < 30 and FLI  $\ge$  60 groups. Other than removing the

553 intermediate FLI participants and resulting new random split to the train (70%) and test (30%) sets,

- these models were constructed identically to the main models, including LOGOCV design, feature
- selection, and hyperparameter optimization. The recommended parameters for this classification task
- 556 were eta=0.00102; gamma=3.7; max\_depth=2; min\_child\_weight=5; subsample=0.49;
- 557 colsample\_bytree=0.631; nrounds=3119. Interpretation of partial dependence was also performed
- identically, but only the relative effects of the model features were plotted without a cladogram.

559

#### 560 Exclusion of validation region data from feature selection and hyperparameter

#### 561 optimization

562 Because training data from all 6 regions is used to inform the selection of optimal features and 563 hyperparameters, the validation region data cannot be considered completely independent from the 564 training of the LOGOCV models. Thus, we constructed a set of classification models for the FLI  $\geq 60$ 565 and FLI < 60 groups, where all validation region samples also in the training data were excluded from 566 the simple intercept of top50 features in each LOGOCV set and from the subsequent hyperparameter 567 optimization. These models with individualized features and hyperparameters were then tested on the 568 validation region samples in the unseen test data to estimate how model performance was affected. The 569 main test (70%) and train (30%) sets were identical to the main models, but additionally 6 randomized 570 70/30 splits nested inside the test set (excluding the validation region) were used in hyperparameter 571 optimization to reduce overfitting. Average optimal hyperparameters in the 6 models were 572 eta=0.00106; gamma=4.3; max\_depth=2; min\_child\_weight=7; subsample=0.36; 573 colsample bytree=0.613; nrounds=1772.

574

#### 575 Identification of predictive features specific to liver function

576 Because the FLI also incorporates BMI and waist circumference, and they strongly contribute to the 577 index (Bedogni et al., 2006), we deemed it necessary to further investigate which of the identified 578 balances were specific to liver function. The participants were first grouped by age (< 40, 40 - 60, and 579 60 <), sex (female or male) and BMI (< 25, 25 – 30, and 30 <) into 18 categories ( $N = 105 \sim 711$  per 580 category). We performed feature selection similarly to the FLI models by fitting random forest 581 regressors for GGT and triglycerides with mlr 2.16.0 (Bischl et al., 2016). This was done separately in 582 each of the 18 categories, and in each category, we again used LOGOCV with the regions to obtain 6 583 runs per category. Finally, the features predictive of GGT or triglycerides in each category were

selected as the intersect of top 50 features in the 6 LOGOCV iterations by permutation importance. The intersect of features predictive of GGT or triglycerides in any of the categories and the features predictive of categorical FLI were identified as specific to liver function.

587

#### 588 Pathway inference for taxa associated with FLI

589 Our taxonomic matching of the reads is based on the genomes of GTDB (release 89; Parks et al., 590 2018), which are all complete or nearly complete and available in online databases. This enables us to 591 estimate the likely genetic content, and thus, the metabolic potential of the microbes associated with 592 FLI. We use this approach because the sequencing depth of our samples does not allow assembling 593 contigs and (metagenome-assembled) genomes, required for pathway predictions. Because of the 594 compositional phylogenetic transform, among other features of our data, previously developed 595 approaches such as PICRUSt (Douglas et al., 2019) could not be used here.

596

597 The genomes of all 336 bacteria under at least one of the predictive balances were downloaded from 598 NCBI. 119 of these genomes were originally not annotated, which is a requirement for pathway 599 prediction. Therefore, Prokka v1.14.6 (Seemann, 2014) was used to annotate the 119 unannotated 600 genomes as a preliminary step. Pathway predictions were then performed for all 336 genomes with 601 mpwt v0.5.3 (Belcour et al., 2019) multiprocessing tool for the PathoLogic pipeline of Pathway Tools 602 23.0 (Karp et al., 2019). Pathways for ethanol and short chain fatty acid (acetate, butyrate, propionate) 603 production, bile acid metabolism, and choline degradation to trimethylamine were identified from 604 MetaCyc pathway classifications (Caspi et al., 2018; **Table S4**). The prevalence of these processes was 605 then assessed in the analyzed genomes and summarized per process to consider the possible links of the taxa with fatty liver pathophysiology. Finally, the presence of individual pathways for acetate and 606 607 ethanol production was also outlined for each genome.

#### 608

### 609 **Declarations**

- 610 Ethics approval and consent to participate
- 611 The Coordinating Ethics Committee of the Helsinki University Hospital District approved our study
- 612 protocol (Ref. 558/E3/2001). All participants have given their written informed consent.

#### 613 **Consent for publication**

614 Not applicable.

#### 615 Availability of data and material

616 The analysis code written for this study is included with the Supplementary Information. The datasets

- 617 generated during and analyzed during the current study are not public, but are available based on a
- 618 written application to the THL Biobank as instructed in: <u>https://thl.fi/en/web/thl-biobank/for-</u>
- 619 <u>researchers</u>

#### 620 **Competing interests**

621 V.S. has consulted for Novo Nordisk and Sanofi and received honoraria from these companies. He also

has ongoing research collaboration with Bayer AG, all unrelated to this study. R.L. serves as a

623 consultant or advisory board member for Anylam/Regeneron, Arrowhead Pharmaceuticals,

624 AstraZeneca, Bird Rock Bio, Boehringer Ingelheim, Bristol-Myer Squibb, Celgene, Cirius, CohBar,

625 Conatus, Eli Lilly, Galmed, Gemphire, Gilead, Glympse bio, GNI, GRI Bio, Inipharm, Intercept, Ionis,

626 Janssen Inc., Merck, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer,

627 Prometheus, Promethera, Sanofi, Siemens, and Viking Therapeutics. In addition, his institution has

- 628 received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Cirius, Eli Lilly
- and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Grail,

- 630 Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NuSirt, Pfizer, pH Pharma,
- 631 Prometheus, and Siemens. He is also co-founder of Liponexus, Inc.
- 632 Funding
- 633 This research was supported in part by grants from the Finnish Foundation for Cardiovascular
- 634 Research, the Emil Aaltonen Foundation, the Paavo Nurmi Foundation, the Urmas Pekkala Foundation,
- the Finnish Medical Foundation, the Sigrid Juselius Foundation, the Academy of Finland (#321356 to
- 636 A.H.; #295741, #307127 to L.L.; #321351 to T.N.) and the National Institutes of Health
- 637 (R01ES027595 to M.J.). R.L. receives funding support from NIEHS (5P42ES010337), NCATS
- 638 (5UL1TR001442), NIDDK (U01DK061734, R01DK106419, P30DK120515, R01DK121378,
- 639 R01DK124318), and DOD PRCRP (W81XWH-18-2-0026). Additional support was provided by
- 640 Illumina, Inc. and Janssen Pharmaceutica through their sponsorship of the Center for Microbiome
- 641 Innovation at UCSD.


#### 642 Authors' contributions

- M.R., F.Å., V.M., V.S., R.K, L.L and T.N designed the work. A.H., L.V., G.M., P.J., V.S., M.J and
- 644 R.K. acquired the data. M.R., L.L. and T.N. analyzed the data. M.R. wrote the manuscript in
- 645 consultation with all authors. M.I., P.J., V.S., R.K., L.L. and T.N. supervised the work. All authors
- 646 gave final approval of the version to be published.

#### 647 Acknowledgements

- 648 We thank all participants of the FINRISK 2002 survey for their contributions to this work, and Tara
- 649 Schwartz for assistance with laboratory work.

650 Figures



**Figure 1.** Distribution of FLI (A), its components (B), and FLI in quantiles of the first three PC

652 components of the fecal bacterial composition of the participants (C). The cutoff at FLI = 60 used to

653 divide the participants is indicated with a dashed line in panels A and C.




Figure 2. Relative effects of predictive balances and covariates on the FLI < 60 and FLI  $\ge$  60 654 655 classification model (AUC = 0.75) predictions. Nodes of the balances are indicated in the cladogram 656 and the relative effect sizes of their clades (opposite sides of each balance) are shown in the associated 657 heatmap. The relative effect sizes of the covariates (age and sex) are shown below the legend with a 658 heatmap on the same scale as was used for the balances. The two liver-specific balances associated 659 with triglyceride and GGT levels are indicated with bold font. Clades with redundant information have 660 been collapsed but their major genera are indicated. The complete tree is included in Figure S3. Gut microbiome composition and fatty liver 29

# 661 **References**

- Alexander, M., Loomis, A. K., Fairburn-Beech, J., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra,
   D., et al. (2018). Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease.
   *BMC Medicine* 16, 130. doi:10.1186/s12916-018-1103-x.
- Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., et al. (2020). Gut
   microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
   *Nature Reviews Gastroenterology & Hepatology* 17, 279–297. doi:10.1038/s41575-020-0269-9.
- Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. (2006).
  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general
  population. *BMC Gastroenterol* 6, 33. doi:10.1186/1471-230X-6-33.
- Belcour, A., Frioux, C., Aite, M., Bretaudeau, A., and Siegel, A. (2019). Metage2Metabo: metabolic
  complementarity applied to genomes of large-scale microbiotas for the identification of
  keystone species. *bioRxiv*, 803056. doi:10.1101/803056.
- Bischl, B., Lang, M., Kotthoff, L., Schiffner, J., Richter, J., Studerus, E., et al. (2016). mlr: Machine
  Learning in R. *Journal of Machine Learning Research* 17, 1–5.
- Bischl, B., Richter, J., Bossek, J., Horn, D., Thomas, J., and Lang, M. (2018). mlrMBO: A Modular
  Framework for Model-Based Optimization of Expensive Black-Box Functions. *arXiv:1703.03373 [stat]*. Available at: http://arxiv.org/abs/1703.03373 [Accessed February 18, 2020].
- Bommert, A., Sun, X., Bischl, B., Rahnenführer, J., and Lang, M. (2020). Benchmark for filter methods
   for feature selection in high-dimensional classification data. *Computational Statistics & Data Analysis* 143, 106839. doi:10.1016/j.csda.2019.106839.
- Borodulin, K., Tolonen, H., Jousilahti, P., Jula, A., Juolevi, A., Koskinen, S., et al. (2018). Cohort
  Profile: The National FINRISK Study. *International Journal of Epidemiology* 47, 696–696i.
  doi:10.1093/ije/dyx239.
- Borodulin, K., Vartiainen, E., Peltonen, M., Jousilahti, P., Juolevi, A., Laatikainen, T., et al. (2015).
  Forty-year trends in cardiovascular risk factors in Finland. *Eur J Public Health* 25, 539–546.
  doi:10.1093/eurpub/cku174.
- Canfora, E. E., Meex, R. C. R., Venema, K., and Blaak, E. E. (2019). Gut microbial metabolites in
  obesity, NAFLD and T2DM. *Nature Reviews Endocrinology* 15, 261–273. doi:10.1038/s41574019-0156-z.
- 692 Carpino, G., Del Ben, M., Pastori, D., Carnevale, R., Baratta, F., Overi, D., et al. (2019). Increased
  693 liver localization of lipopolysaccharides in human and experimental non-alcoholic fatty liver
  694 disease. *Hepatology*, hep.31056. doi:10.1002/hep.31056.
- Caspi, R., Billington, R., Fulcher, C. A., Keseler, I. M., Kothari, A., Krummenacker, M., et al. (2018).
  The MetaCyc database of metabolic pathways and enzymes. *Nucleic Acids Res* 46, D633–
  D639. doi:10.1093/nar/gkx935.

- Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., et al. (2019). A gut
   microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. *Nature Communications* 10, 1406. doi:10.1038/s41467-019-09455-9.
- Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., et al. (2012). The
  diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the
  American Association for the Study of Liver Diseases, American College of Gastroenterology,
  and the American Gastroenterological Association. *Hepatology* 55, 2005–2023.
  doi:10.1002/hep.25762.
- Chen, T., and Guestrin, C. (2016). XGBoost: A Scalable Tree Boosting System. *Proceedings of the* 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining KDD '16, 785–794. doi:10.1145/2939672.2939785.
- Cheng, H.-Y., Wang, H.-Y., Chang, W.-H., Lin, S.-C., Chu, C.-H., Wang, T.-E., et al. (2013).
  Nonalcoholic Fatty Liver Disease: Prevalence, Influence on Age and Sex, and Relationship with
  Metabolic Syndrome and Insulin Resistance. *International Journal of Gerontology* 7, 194–198.
  doi:10.1016/j.ijge.2013.03.008.
- Compare, D., Coccoli, P., Rocco, A., Nardone, O. M., De Maria, S., Cartenì, M., et al. (2012). Gut–
  liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases* 22, 471–476. doi:10.1016/j.numecd.2012.02.007.
- de Faria Ghetti, F., Oliveira, D. G., de Oliveira, J. M., de Castro Ferreira, L. E. V. V., Cesar, D. E., and
  Moreira, A. P. B. (2018). Influence of gut microbiota on the development and progression of
  nonalcoholic steatohepatitis. *Eur J Nutr* 57, 861–876. doi:10.1007/s00394-017-1524-x.
- Dehoux, P., Marvaud, J. C., Abouelleil, A., Earl, A. M., Lambert, T., and Dauga, C. (2016).
  Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals speciesspecific genomic properties and numerous putative antibiotic resistance determinants. *BMC Genomics* 17, 819. doi:10.1186/s12864-016-3152-x.
- Deschasaux, M., Bouter, K. E., Prodan, A., Levin, E., Groen, A. K., Herrema, H., et al. (2018).
  Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. *Nature Medicine* 24, 1526–1531. doi:10.1038/s41591-018-0160-1.
- Diether, N. E., and Willing, B. P. (2019). Microbial Fermentation of Dietary Protein: An Important
   Factor in Diet–Microbe–Host Interaction. *Microorganisms* 7.
   doi:10.3390/microorganisms7010019.
- Douglas, G. M., Maffei, V. J., Zaneveld, J., Yurgel, S. N., Brown, J. R., Taylor, C. M., et al. (2019).
   PICRUSt2: An improved and extensible approach for metagenome inference. *bioRxiv*, 672295.
   doi:10.1101/672295.
- Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., and Knight, R. (2018).
  Current understanding of the human microbiome. *Nat. Med.* 24, 392–400.
  doi:10.1038/nm.4517.

- Glenn, T. C., Nilsen, R. A., Kieran, T. J., Sanders, J. G., Bayona-Vásquez, N. J., Finger, J. W., et al.
  (2019). Adapterama I: universal stubs and primers for 384 unique dual-indexed or 147,456
  combinatorially-indexed Illumina libraries (iTru & iNext). *PeerJ* 7, e7755.
  doi:10.7717/peerj.7755.
- Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V., and Egozcue, J. J. (2017). Microbiome Datasets
  Are Compositional: And This Is Not Optional. *Front Microbiol* 8.
  doi:10.3389/fmicb.2017.02224.
- Greenwell, B. M. (2017). pdp: An R Package for Constructing Partial Dependence Plots. *The R Journal*9, 421–436.
- Haas, J. T., Francque, S., and Staels, B. (2016). Pathophysiology and Mechanisms of Nonalcoholic
  Fatty Liver Disease. *Annual Review of Physiology* 78, 181–205. doi:10.1146/annurev-physiol021115-105331.
- He, Y., Wu, W., Zheng, H.-M., Li, P., McDonald, D., Sheng, H.-F., et al. (2018). Regional variation
  limits applications of healthy gut microbiome reference ranges and disease models. *Nature Medicine* 24, 1532–1535. doi:10.1038/s41591-018-0164-x.
- Hillmann, B., Al-Ghalith, G. A., Shields-Cutler, R. R., Zhu, Q., Gohl, D. M., Beckman, K. B., et al.
  (2018). Evaluating the Information Content of Shallow Shotgun Metagenomics. *mSystems* 3.
  doi:10.1128/mSystems.00069-18.
- Hillmann, B., Al-Ghalith, G. A., Shields-Cutler, R. R., Zhu, Q., Knight, R., and Knights, D. (2020).
  SHOGUN: a modular, accurate, and scalable framework for microbiome quantification. *Bioinformatics*, btaa277. doi:10.1093/bioinformatics/btaa277.
- Jiang, W., Wu, N., Wang, X., Chi, Y., Zhang, Y., Qiu, X., et al. (2015). Dysbiosis gut microbiota
  associated with inflammation and impaired mucosal immune function in intestine of humans
  with non-alcoholic fatty liver disease. *Sci Rep* 5, 8096. doi:10.1038/srep08096.
- Jiao, N., Wu, D., Yang, Z., Fang, S., Li, X., Yuan, M., et al. (2019). Gut bacteria contributes to
   NAFLD pathogenesis by promoting secondary bile acids biosynthesis. *The FASEB Journal* 33, 126.4-126.4. doi:10.1096/fasebj.2019.33.1\_supplement.126.4.
- Karp, P. D., Midford, P. E., Billington, R., Kothari, A., Krummenacker, M., Latendresse, M., et al.
  (2019). Pathway Tools version 23.0 update: software for pathway/genome informatics and
  systems biology. *Briefings in Bioinformatics*, bbz104. doi:10.1093/bib/bbz104.
- Kerminen, S., Havulinna, A. S., Hellenthal, G., Martin, A. R., Sarin, A.-P., Perola, M., et al. (2017).
  Fine-Scale Genetic Structure in Finland. *G3: Genes, Genomes, Genetics* 7, 3459–3468.
  doi:10.1534/g3.117.300217.
- Kim, D., Song, L., Breitwieser, F. P., and Salzberg, S. L. (2016). Centrifuge: rapid and sensitive
   classification of metagenomic sequences. *Genome Res.* doi:10.1101/gr.210641.116.

- Kim, H.-N., Joo, E.-J., Cheong, H. S., Kim, Y., Kim, H.-L., Shin, H., et al. (2019). Gut Microbiota and
   Risk of Persistent Nonalcoholic Fatty Liver Diseases. *Journal of Clinical Medicine* 8, 1089.
   doi:10.3390/jcm8081089.
- Koehler, E. M., Schouten, J. N. L., Hansen, B. E., Hofman, A., Stricker, B. H., and Janssen, H. L. A.
  (2013). External Validation of the Fatty Liver Index for Identifying Nonalcoholic Fatty Liver
  Disease in a Population-based Study. *Clinical Gastroenterology and Hepatology* 11, 1201–
  1204. doi:10.1016/j.cgh.2012.12.031.
- Liu, Y., Meric, G., Havulinna, A. S., Teo, S. M., Ruuskanen, M., Sanders, J., et al. (2020). Early
   prediction of liver disease using conventional risk factors and gut microbiome-augmented
   gradient boosting. Genetic and Genomic Medicine doi:10.1101/2020.06.24.20138933.
- Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T. A., et al. (2019). Sex
   Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research
   Gaps. *Hepatology* 70, 1457–1469. doi:10.1002/hep.30626.
- Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., et al. (2017). Gut MicrobiomeBased Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human
  Nonalcoholic Fatty Liver Disease. *Cell Metabolism* 25, 1054-1062.e5.
  doi:10.1016/j.cmet.2017.04.001.
- Louca, S., Polz, M. F., Mazel, F., Albright, M. B. N., Huber, J. A., O'Connor, M. I., et al. (2018).
  Function and functional redundancy in microbial systems. *Nat Ecol Evol* 2, 936–943.
  doi:10.1038/s41559-018-0519-1.
- Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., et al. (2003).
   Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 37, 917–923.
   doi:10.1053/jhep.2003.50161.
- McMurdie, P. J., and Holmes, S. (2013). phyloseq: An R package for reproducible interactive analysis
   and graphics of microbiome census data. *PLoS ONE* 8, e61217.
   doi:10.1371/journal.pone.0061217.
- Méric, G., Wick, R. R., Watts, S. C., Holt, K. E., and Inouye, M. (2019). Correcting index databases
   improves metagenomic studies. *bioRxiv*, 712166. doi:10.1101/712166.
- Meslier, V., Laiola, M., Roager, H. M., Filippis, F. D., Roume, H., Quinquis, B., et al. (2020).
  Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. *Gut.*doi:10.1136/gutjnl-2019-320438.
- Miele, L., Valenza, V., Torre, G. L., Montalto, M., Cammarota, G., Ricci, R., et al. (2009). Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.
   *Hepatology* 49, 1877–1887. doi:10.1002/hep.22848.
- Mohan, R., Namsolleck, P., Lawson, P. A., Osterhoff, M., Collins, M. D., Alpert, C.-A., et al. (2006).
   Clostridium asparagiforme sp. nov., isolated from a human faecal sample. *Systematic and Applied Microbiology* 29, 292–299. doi:10.1016/j.syapm.2005.11.001.

- Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., et al. (2013).
  Intestinal microbiota in patients with nonalcoholic fatty liver disease. *Hepatology* 58, 120–127.
  doi:10.1002/hep.26319.
- Murray, W. D., Khan, A. W., and van den BERG, L. (1982). Clostridium saccharolyticum sp. nov., a
  Saccharolytic Species from Sewage Sludge. *International Journal of Systematic Bacteriology*32, 132–135. doi:10.1099/00207713-32-1-132.
- Näyhä, S. (1989). Geographical variations in cardiovascular mortality in Finland, 1961-1985. Scand J
   Soc Med Suppl 40, 1–48.
- 816 Oksanen, J., Blanchet, F. G., Friendly, M., Kindt, R., Legendre, P., McGlinn, D., et al. (2018). *vegan:* 817 *Community Ecology Package*. Available at: https://CRAN.R-project.org/package=vegan
   818 [Accessed June 4, 2018].
- Parks, D. H., Chuvochina, M., Chaumeil, P.-A., Rinke, C., Mussig, A. J., and Hugenholtz, P. (2020). A
  complete domain-to-species taxonomy for Bacteria and Archaea. *Nature Biotechnology*, 1–8.
  doi:10.1038/s41587-020-0501-8.
- Parks, D. H., Chuvochina, M., Waite, D. W., Rinke, C., Skarshewski, A., Chaumeil, P.-A., et al.
  (2018). A standardized bacterial taxonomy based on genome phylogeny substantially revises
  the tree of life. *Nat Biotechnol* 36, 996–1004. doi:10.1038/nbt.4229.
- Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., et al. (2014). Alterations of the human gut
  microbiome in liver cirrhosis. *Nature* 513, 59–64. doi:10.1038/nature13568.
- R Core Team (2018). *R: A language and environment for statistical computing*. Vienna, Austria: R
   Foundation for Statistical Computing Available at: https://www.R-project.org/ [Accessed
   March 4, 2019].
- Rinella, M., and Charlton, M. (2016). The globalization of nonalcoholic fatty liver disease: Prevalence
  and impact on world health. *Hepatology* 64, 19–22. doi:10.1002/hep.28524.
- Safari, Z., and Gérard, P. (2019). The links between the gut microbiome and non-alcoholic fatty liver
  disease (NAFLD). *Cell. Mol. Life Sci.* 76, 1541–1558. doi:10.1007/s00018-019-03011-w.
- Salosensaari, A., Laitinen, V., Havulinna, A. S., Meric, G., Cheng, S., Perola, M., et al. (2020).
   Taxonomic Signatures of Long-Term Mortality Risk in Human Gut Microbiota. Epidemiology doi:10.1101/2019.12.30.19015842.
- Sanders, J. G., Nurk, S., Salido, R. A., Minich, J., Xu, Z. Z., Zhu, Q., et al. (2019). Optimizing
  sequencing protocols for leaderboard metagenomics by combining long and short reads. *Genome Biology* 20, 226. doi:10.1186/s13059-019-1834-9.
- Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–2069.
  doi:10.1093/bioinformatics/btu153.

- Sharpton, S. R., Ajmera, V., and Loomba, R. (2019). Emerging Role of the Gut Microbiome in
   Nonalcoholic Fatty Liver Disease: From Composition to Function. *Clinical Gastroenterology and Hepatology* 17, 296–306. doi:10.1016/j.cgh.2018.08.065.
- Shen, F., Zheng, R.-D., Sun, X.-Q., Ding, W.-J., Wang, X.-Y., and Fan, J.-G. (2017). Gut microbiota
  dysbiosis in patients with non-alcoholic fatty liver disease. *Hepatobiliary & Pancreatic Diseases International* 16, 375–381. doi:10.1016/S1499-3872(17)60019-5.
- Silverman, J. D., Washburne, A. D., Mukherjee, S., and David, L. A. (2017). A phylogenetic transform
  enhances analysis of compositional microbiota data. *eLife* 6, e21887. doi:10.7554/eLife.21887.
- Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., and Fodor, A. A. (2011).
  Association Between Composition of the Human Gastrointestinal Microbiome and
  Development of Fatty Liver With Choline Deficiency. *Gastroenterology* 140, 976–986.
  doi:10.1053/j.gastro.2010.11.049.
- Suzuki, T. A., and Worobey, M. (2014). Geographical variation of human gut microbial composition.
   *Biology Letters* 10, 20131037. doi:10.1098/rsbl.2013.1037.

Toshikuni, N., Tsutsumi, M., and Arisawa, T. (2014). Clinical differences between alcoholic liver
disease and nonalcoholic fatty liver disease. *World J Gastroenterol* 20, 8393–8406.
doi:10.3748/wjg.v20.i26.8393.

- Vanni, E., and Bugianesi, E. (2015). Editorial: utility and pitfalls of Fatty Liver Index in epidemiologic
  studies for the diagnosis of NAFLD. *Aliment Pharmacol Ther* 41, 406–407.
  doi:10.1111/apt.13063.
- Wigg, A. J., Roberts-Thomson, I. C., Dymock, R. B., McCarthy, P. J., Grose, R. H., and Cummins, A.
  G. (2001). The role of small intestinal bacterial overgrowth, intestinal permeability,
  endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. *Gut* 48, 206–211. doi:10.1136/gut.48.2.206.
- Yki-Järvinen, H. (2014). Non-alcoholic fatty liver disease as a cause and a consequence of metabolic
   syndrome. *Lancet Diabetes Endocrinol* 2, 901–910. doi:10.1016/S2213-8587(14)70032-4.
- Yu, G., Smith, D. K., Zhu, H., Guan, Y., and Lam, T. T.-Y. (2017). ggtree: an r package for
  visualization and annotation of phylogenetic trees with their covariates and other associated
  data. *Methods in Ecology and Evolution* 8, 28–36. doi:10.1111/2041-210X.12628.
- Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., et al. (2019). Fatty Liver Disease Caused by HighAlcohol-Producing Klebsiella pneumoniae. *Cell Metabolism* 30, 675-688.e7.
  doi:10.1016/j.cmet.2019.08.018.
- Zhao, S., Jang, C., Liu, J., Uehara, K., Gilbert, M., Izzo, L., et al. (2020). Dietary fructose feeds hepatic
  lipogenesis via microbiota-derived acetate. *Nature* 579, 586–591. doi:10.1038/s41586-0202101-7.

Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., et al. (2013). Characterization of gut
microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between
endogenous alcohol and NASH. *Hepatology* 57, 601–609. doi:10.1002/hep.26093.